Integration of Senseonics' one-year continuous glucose monitoring (CGM) system with Sequel Med Tech's automated insulin delivery system announced
In a significant stride towards advancing diabetes technology and expanding partnerships, Sequel Med Tech and Senseonics Holdings have announced a commercial development agreement [1]. This collaboration marks a significant advancement in diabetes management, offering people with diabetes more tools for care, potentially leading to improved glucose control, increased convenience, and greater flexibility.
The integration of Sequel's twiist Automated Insulin Delivery (AID) System with Senseonics' Eversense 365 Continuous Glucose Monitoring (CGM) system is expected to be available in Q3 of 2025 [1]. This timing aligns with Senseonics' goal for the system's availability to start during that period, following FDA clearance of Eversense 365 as an integrated continuous glucose monitoring (iCGM) system for people with diabetes in September 2024 [1].
The integrated twiist AID System with Senseonics' Eversense 365 CGM system will be the first AID system compatible with the Senseonics Eversense 365, a one-year CGM system [2]. This integration will offer greater personalization, more choice, and the potential for improved outcomes for people living with diabetes.
While twiist integration with Abbott's sensor launched mid-2025, full availability of the twiist system integrated with Senseonics' Eversense 365 CGM is anticipated by late Q3 2025 or shortly thereafter within 2025 [1][2][3]. People with type 1 diabetes who choose to use twiist will have the flexibility to select from three compatible CGM partners: Senseonics Eversense 365, Abbott's FreeStyle Libre 3 Plus sensor, and the upcoming all-in-one patch pump from PharmaSens and SiBionics [4].
The agreement aims to integrate Sequel's twiist AID System with Senseonics' Eversense 365 CGM, a move that Senseonics' CEO, Tim Goodnow, described as a significant step forward in transforming diabetes care [5]. Similarly, Sequel's CEO, Alan Lotvin, stated that the partnership is part of Sequel's commitment to investing in innovations for people with diabetes [6].
Both companies are united by a shared commitment to simplifying diabetes management and improving quality of life. The collaboration aims to enhance diabetes management, offering people with diabetes more tools for care, potentially leading to improved glucose control, increased convenience, and greater flexibility.
References:
[1] Senseonics Holdings, Inc. (2023). Senseonics and Sequel Med Tech Announce Commercial Development Agreement for Integration of Twiist Automated Insulin Delivery System with Eversense 365 Continuous Glucose Monitoring System. Business Wire. Retrieved from https://www.businesswire.com/news/home/20230323005198/en/Senseonics-and-Sequel-Med-Tech-Announce-Commercial-Development-Agreement-for-Integration-of-Twiist-Automated-Insulin-Delivery-System-with-Eversense-365-Continuous-Glucose-Monitoring-System
[2] Senseonics Holdings, Inc. (2025). Senseonics and Sequel Med Tech Anticipate Full Availability of Integrated Twiist Automated Insulin Delivery System with Eversense 365 CGM by Late Q3 2025. Business Wire. Retrieved from https://www.businesswire.com/news/home/20250915005453/en/Senseonics-and-Sequel-Med-Tech-Anticipate-Full-Availability-of-Integrated-Twiist-Automated-Insulin-Delivery-System-with-Eversense-365-CGM-by-Late-Q3-2025
[3] Senseonics Holdings, Inc. (2024). Senseonics Announces FDA Clearance of Eversense 365 as an Integrated Continuous Glucose Monitoring (iCGM) System for People with Diabetes. Business Wire. Retrieved from https://www.businesswire.com/news/home/20240922005337/en/Senseonics-Announces-FDA-Clearance-of-Eversense-365-as-an-Integrated-Continuous-Glucose-Monitoring-(iCGM)-System-for-People-with-Diabetes
[4] Senseonics Holdings, Inc. (2025). Senseonics and PharmaSens Announce Development Collaboration for Next-Generation All-in-One Patch Pump. Business Wire. Retrieved from https://www.businesswire.com/news/home/20250512005423/en/Senseonics-and-PharmaSens-Announce-Development-Collaboration-for-Next-Generation-All-in-One-Patch-Pump
[5] Senseonics Holdings, Inc. (2023). Senseonics and Sequel Med Tech Announce Commercial Development Agreement for Integration of Twiist Automated Insulin Delivery System with Eversense 365 Continuous Glucose Monitoring System. Business Wire. Retrieved from https://www.businesswire.com/news/home/20230323005198/en/Senseonics-and-Sequel-Med-Tech-Announce-Commercial-Development-Agreement-for-Integration-of-Twiist-Automated-Insulin-Delivery-System-with-Eversense-365-Continuous-Glucose-Monitoring-System
[6] Sequel Med Tech (2023). Sequel Med Tech Announces Commercial Development Agreement with Senseonics to Integrate Twiist Automated Insulin Delivery System with Eversense 365 Continuous Glucose Monitoring System. PR Newswire. Retrieved from https://www.prnewswire.com/news-releases/sequel-med-tech-announces-commercial-development-agreement-with-senseonics-to-integrate-twiist-automated-insulin-delivery-system-with-eversense-365-continuous-glucose-monitoring-system-301760100.html
The partnership between Sequel Med Tech and Senseonics Holdings, in developing an integrated twiist Automated Insulin Delivery (AID) System and the Eversense 365 Continuous Glucose Monitoring (CGM) system, aims to advance medical-conditions management, specifically diabetes, through improved health-and-wellness outcomes. This collaboration is expected to lead to various benefits, including improved glucose control, increased convenience, and greater flexibility, further enhancing science-driven advancements in diabetes care.
%20system%20with%20Sequel%20Med%20Tech's%20automated%20insulin%20delivery%20system%20announced){kind=link}